Portrait: Takeda lives diversity

Takeda, the global biopharmaceutical company, has a history of more than 240 years rich in tradition and always characterized by further development and innovation. In Germany, however, the focus of Takeda is not only on shaping progress in the…

5 Min
More

Open House Charité BIH Innovation: The New Innovation Site "Am Zirkus" Celebrates Its Opening

After two years of intensive renovation work, the new location of Charité BIH Innovation (CBI) - the joint technology transfer of Charité and BIH - has opened on October 12. Covering a total of 2,500 m2 spread over four floors, the modern, expanded…

5 Min
More

Cancer does not stop at borders – and neither does an approach to personalized cancer therapy developed in Berlin

Reverse Clinical Engineering® is now available to oncologists and cancer patients in Saudi Arabia, the Middle East, and North Africa. ASC Oncology proudly announces new partnership with Tamer Group.

2 Min
More

Bayer Acquires German Biotech Start-up Targenomix

Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery / Targenomix…

4 Min
More

First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial

Berlin/Aalborg, 27 October 2022. The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an international phase 2 trial.

3 Min
More

T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors

 

TK-8001 targets a MAGE-A1 epitope presented on HLA-A*02:01

 

IMAG1NE…

5 Min
More

FyoniBio and Strike Pharma sign a Master Service Agreement covering Cell Line Development for a novel bi-specific therapeutic mAb

Berlin, Germany and Stockholm, Sweden, October 20, 2022:

FyoniBio, a CDO expert specialized in tailored cell line development and Strike Pharma, whose proprietary

Adaptable Drug Affinity Conjugate (ADAC) technology enables development of …

2 Min
More

Special Topic | Long COVID in Berlin-Brandenburg – research, networks and engagement for better care

The term “Long COVID” first emerged in the social media. Numerous affected individuals have reported in the social media about their various, long-lasting health limitations after SARS-CoV-2 infection. In the Berlin-Brandenburg metropolitan region,…

6 Min
More

Berlin-based clinical trials imaging company pharmtrace opens US base

pharmtrace, a German, Berlin based provider of Independent expertise for nuclear medicine, diagnostics, and drug development clinical trials has established a representative office in Philadelphia. pharmtrace is currently enjoying increasing…

1 Min
More

NUVISAN receives US$ 9.6m grant for a multi-target drug discovery program on novel non-hormonal contraceptive medicines

NUVISAN’s integrated drug discovery expertise leveraged in a grant from the Bill & Melinda Gates Foundation

2 Min
More
Show more items